Glaxosmithkline Share News (GSK)

GlaxoSmithKline Begins Dosing In Phase III Sirukumab Study

GlaxoSmithKline Gets Expansion Approval For Volibris In Europe

Circassia Pharmaceuticals Wins Approval For FLIXOTIDE pMDi Equivalent

EU mergers and takeovers (Nov 19)

BRUSSELS, Nov 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Bain Capital Investors to acquire car parts distributor Autodistribution Group (approved Nov. 19) -- Austrian i

Vectura Loss Narrows On Better Royalty Income, Seebri Results Good

BROKER RATINGS SUMMARY: JPMorgan And S&P Capital IQ Positive On ITV

Dividends Calendar - Week Ahead

EU regulator finds no safety issues with GSK, Merck HPV vaccines

LONDON, Nov 5 (Reuters) - European drug regulators have found no safety concerns linking GlaxoSmithKline's and Merck's cervical cancer vaccines with two conditions known as complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS). Concluding a safety review

GlaxoSmithKline's new severe asthma treatment gets FDA approval

(ShareCast News) - GlaxoSmithKline's Nucala (mepolizumab) drug has received approval from the US Food and Drug Administration (FDA) for its Biologics License Application. The FTSE 100 pharmaceutical company revealed the news on Thursday. Nucala has been approved as an add-on maintenance treatment f

US Regulator Approves Glaxo's Nucala To Treat Severe Asthma

Mylan not relying on acquisitions if Perrigo bid fails -chairman

By Steven Scheer TEL AVIV, Nov 4 (Reuters) - Mylan will likely win its bid to take over Irish-based generic drugmaker Perrigo Co , but if the bid fails the company can live without seeking an alternative acquisition, its chairman said on Wednesday. Mylan made an offer for Perrigo in A

UPDATE 3-GSK plan to file up to 20 new drugs by 2020 underwhelms market

* 80 pct of new drugs have potential to be first-in-class * Nucala, Shingrix, anaemia pill, antivirals highlighted * Still sees mid-to-high single digit EPS growth 2016-2020 * Shares fall 1.5 pct (Adds further comment from CEO and analysts, closing shares) By Ben Hirschl

UPDATE 1-Bi-monthly injection blocks HIV in study from J&J and GSK

(Adds additional comments, context) Nov 3 (Reuters) - A long-acting two-drug injection given once every eight weeks worked as well as three daily pills in suppressing HIV, the virus that causes AIDS, according to a clinical trial backed by Johnson & Johnson and GlaxoSmithKline. Paul S

UPDATE: Glaxo Gets Good ViiV Results, Partners With Merck

GSK boss silent on report drugmaker rebuffed Pfizer

LONDON, Nov 3 (Reuters) - GlaxoSmithKline's chief executive declined to comment on Tuesday on a report that Pfizer had approached the British drugmaker about a possible takeover in recent weeks but was rebuffed. Pfizer has since decided to focus on a transaction with Dublin-based Allergan